Sridharan, M <br/><br/>
Circulating fibroblast growth factor-23 increases following intermittent parathyroid hormone (1-34) in postmenopausal osteoporosis: association with biomarker of bone formation.  [electronic resource] 

 -  Calcified tissue international  Nov 2010 
 - 398-405 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>1432-0827 
<br/><br/><label>Standard No.: </label>10.1007/s00223-010-9414-8  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Biomarkers--blood<br/>Bone Density--drug effects<br/>Bone Morphogenetic Proteins--blood<br/>Female<br/>Fibroblast Growth Factor-23<br/>Fibroblast Growth Factors--blood<br/>Humans<br/>Osteogenesis--drug effects<br/>Osteoporosis, Postmenopausal--drug therapy<br/>Peptide Fragments--pharmacology<br/>Teriparatide--analogs & derivatives<br/>Treatment Outcome<br/>Up-Regulation--drug effects